Wednesday, May 02, 2007

Glaxo faces a rude shock

GlaxoSmithKline and its research partner Adolor have abandoned the trials for their experimental drug, Entereg used for treating bowel spasms. One of the ingredients of Entereg is linked with heart attack risks and other serious cardiovascular problems. In some cases, problems like cancer and fractures were also reported. The results of the year long clinical trials on some 800 odd patients have forced the pharma majors to stop further trials. The markets reacted to this news sharply; as a result stocks of Adolor plunged more than 60%. Analysts believe that pharmaceutical companies find it difficult to maintain a balance between a safe and effective drug.

For Complete IIPM Article, Click on IIPM Article

No comments: